GeneWerk Integration Site Analysis - ProtaGene

Cell & Gene Analytics

GeneWerk Integration Site Analysis

hero-animation

GeneWerk Integration Site Analysis

As novel gene therapies enter development pipelines, regulatory bodies adapt their guidelines to ensure their continued safety. Actively and passively integrating (viral) vectors may trigger adverse effects by undirected or unintended integration into the target cell’s genome.

GeneWerk Integration Site Analysis (ISA) is the key tool to assess the biosafety of gene therapy vectors by characterizing their integration profiles, as well as for clonal tracking of genetically modified cells in vivo. Complementary and particularly designed for long term follow-up studies, customized integration site-specific qPCR assays provide an orthogonal method to confirm eventual clonal events.

  • bullet Created with Sketch.

    S-EPTS/LM PCR

  • bullet Created with Sketch.

    TES

  • bullet Created with Sketch.

    (nr)-LAM-PCR

  • bullet Created with Sketch.

    Vector copy number

Powered by GeneWerk

Now a vital part of ProtaGene’s robust analytical capabilities, GeneWerk Integration Site Analysis was developed by gene therapy pioneers and industry leaders who continue to set the standard for vector safety and integration site analysis.

Invented by Dr. Manfred Schmidt and Professor Dr. von Kalle more than two decades ago, GeneWerk scientists work with global clients to develop novel cell and gene therapies that meet regulatory safety requirements and de-risk their cell and gene therapy development journey.

Analytical Solutions from Research to Market

Group Created with Sketch.
Research
Preclinical
Group 2 Created with Sketch.

Discovery – Pre-clinical

Biologic Candidate Evaluation, Optimization and Selection into IND

Group 3 Created with Sketch.
Phase I
Phase II
Phase III
Group 4 Created with Sketch.

Phase I – Phase III

Release, Clinical Data and Characterization Packages for Accelerating Phase I-III Programs through BLA

Group Created with Sketch.
Registration
Market
Group 2 Created with Sketch.

Registration – Market

Commercial-Stage Comparability Testing by Qualified Advanced Methods

Cell and Gene Therapeutic Platform Expertise

Our deep experience assembling a broad range of cell and gene therapy platforms from research through commercialization helps the ProtaGene team design highly effective analytical programs that de-risk development and accelerate timelines to your next key milestones. Key cell and gene therapy platform development areas include:

  • bullet Created with Sketch.

    Capsid-based Vectors

    • AAVs (Multiple Serotypes and Engineered Vectors)
    • Novel Systems
    • Adenovirus
  • bullet Created with Sketch.

    Complex, Envelope Vectors

    • Lentivirus
    • Gammaretrovirus 
    • Novel Viruses
  • bullet Created with Sketch.

    Non-viral Vectors

    • Polynucleotide (RNA/DNA) Formulations
    • Lipid Nanoparticles
    • Transposons
    • Plasmids
  • bullet Created with Sketch.

    Genetic Engineering

    • TALEN
    • CRISPR/Cas9
    • Zinc-finger Nucleases
Our Analytical Systems_Left Created with Sketch.

Analytical Systems

Enabled by state-of-the-art technology, ProtaGene offers an extensive range of analytical capabilities to support your biotherapeutic or gene & cell therapy projects.

Our Analytical Systems_right Created with Sketch.

Subscribe to Our Email List

Consent

Talk to Our Experts

Discover how ProtaGene can support your development programs

Contact Us